• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Acura Pharmaceuticals Announces Second Quarter 2018 Financial Results

    Gabrielle Lakusta
    Aug. 15, 2018 08:40AM PST
    Pharmaceutical Investing

    Acura Pharmaceuticals (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and six months ended June 30, 2018. As quoted in the press release: The Company reported a net loss of $2.8 million or $0.13 per diluted share for the six months ended June 30, 2018, compared to a …

    Acura Pharmaceuticals (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and six months ended June 30, 2018.

    As quoted in the press release:

    The Company reported a net loss of $2.8 million or $0.13 per diluted share for the six months ended June 30, 2018, compared to a net loss of $1.7 million or $0.15 per diluted share for the same period in 2017. For the second quarter 2018, the Company reported a net loss of $1.3 million or $0.06 per diluted share compared to a net loss of $2.2 million or $0.18 per diluted share for the same period in 2017.

    For the six months ended June 30, 2018, the Company recorded $0.3 million in royalty revenue as compared to $0.1 million for the same period in 2017. For the six month period ended December 31, 2017, the Company also recorded $2.5 million in license fee revenue derived from the March 2017 license agreement with MainPointe Pharmaceuticals, LLC, whereas we licensed our NEXAFED product line to them and $0.1 million in each of NEXAFED® product line net sales and collaboration revenue.

    Click here to read the full press release.

    acura pharmaceuticalspharmaceutical investingotcqb:acur
    The Conversation (0)

    Go Deeper

    AI Powered
    ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives.

    ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives.

    Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance

    Latest News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Cardiol Therapeutics

    CRDL:CA

    Invion Limited

    IVX:AU

    Principal Technologies

    PTEC:CC
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES